Report of Foreign Issuer (6-k)
February 28 2018 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of
February 2018
Commission File Number:
001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
Attached hereto and incorporated by reference herein are the following exhibits:
99.1
CEO Letter to Shareholders.
99.2
Press Release: Evogene Reports Fourth Quarter and Full Year 2017 Financial Results.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: February 28, 2018
|
|
EVOGENE LTD.
(Registrant)
By: /s/ Alex Taskar
——————————————
Alex Taskar
Chief Financial Officer
|
EXHIBIT INDEX
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
